IDEAYA Biosciences: Business Model, SWOT Analysis, and Competitors 2026

IDEAYA Biosciences, Inc. stands as a leading company in Healthcare. Generating $218.71 million in annual revenue (growing 55.4% year-over-year) and carrying a market capitalization of $2.90 billion, the company has cemented its position as a foundational player in the global Biotechnology landscape. Under the leadership of its leadership team, IDEAYA Biosciences, Inc. continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines IDEAYA Biosciences, Inc.'s business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating IDEAYA Biosciences, Inc. as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define IDEAYA Biosciences, Inc.'s position in the Biotechnology market today.

What You Will Learn

1. How IDEAYA Biosciences, Inc. generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering IDEAYA Biosciences, Inc.'s competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who IDEAYA Biosciences, Inc.'s main competitors are and how the company compares on key financial metrics
4. IDEAYA Biosciences, Inc.'s key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. IDEAYA Biosciences, Inc.'s strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $218.71 million annual revenue (TTM), +55.4% YoY
• Market Cap: $2.90 billion — one of the largest companies in the Healthcare sector
• Profitability: Gross margin -43.9%, operating margin -869.5%, net margin -52.0%
• Free Cash Flow: $-52.47 million
• Return on Equity: -10.9% — reflects current investment phase
• Employees: 145 worldwide

Who Owns IDEAYA Biosciences, Inc.?

IDEAYA Biosciences, Inc. is publicly traded on the NMS under the ticker symbol IDYA. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of IDEAYA Biosciences, Inc. are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

IDEAYA Biosciences, Inc. has approximately 0.09 billion shares outstanding, with float shares of 0.00 billion — the freely tradeable portion. The stock trades at $33.03 per share as of early 2026.

IDEAYA Biosciences, Inc.'s Mission Statement

IDEAYA Biosciences, Inc.'s strategic mission is aligned with its core business activities in the Biotechnology sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — IDEAYA Biosciences, Inc.'s most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For IDEAYA Biosciences, Inc., the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, IDEAYA Biosciences, Inc.'s strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does IDEAYA Biosciences, Inc. Make Money?

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer driven by GNAQ/11 mutations, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor that is in a Phase 1 clinical trial for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is

IDEAYA Biosciences, Inc.'s business model is built around delivering value to its customers in the Biotechnology segment of the Healthcare sector. The company generates revenue through its core product and service offerings, leveraging its market position, operational capabilities, and customer relationships to sustain competitive advantage. Like most companies in Biotechnology, IDEAYA Biosciences, Inc.'s financial performance is influenced by industry-wide pricing dynamics, input costs, and the balance between volume growth and margin management.

Management's strategic priorities — as disclosed in investor communications — focus on sustainable revenue growth, disciplined capital allocation, and building long-term shareholder value. Investors should review IDEAYA Biosciences, Inc.'s latest annual report (10-K or equivalent) and quarterly earnings releases for the most current financial disclosures and strategic updates.

IDEAYA Biosciences, Inc. Business Model Canvas

The Business Model Canvas framework provides a structured view of how IDEAYA Biosciences, Inc. creates, delivers, and captures value.

Key Partners: IDEAYA Biosciences, Inc.'s key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Biotechnology sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: IDEAYA Biosciences, Inc.'s most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: IDEAYA Biosciences, Inc.'s critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (145 employees), proprietary technology, and financial resources ($639.39M in cash).

Value Propositions: IDEAYA Biosciences, Inc. delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Biotechnology market.

Customer Relationships: IDEAYA Biosciences, Inc. maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: IDEAYA Biosciences, Inc. reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: IDEAYA Biosciences, Inc. serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: IDEAYA Biosciences, Inc.'s major costs include cost of goods sold (143.9% of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 969.5% of revenue.

Revenue Streams: IDEAYA Biosciences, Inc. generates revenue through its core product and service offerings.

IDEAYA Biosciences, Inc. Competitors

IDEAYA Biosciences, Inc. competes against Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Pfizer (PFE), AbbVie (ABBV), Eli Lilly (LLY) and others in the Biotechnology segment of the Healthcare sector.

IDEAYA Biosciences, Inc. SWOT Analysis

A SWOT analysis examines IDEAYA Biosciences, Inc.'s internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Revenue Growth: Revenue grew 55.4% year-over-year to $218.71M, indicating strong demand for IDEAYA Biosciences, Inc.'s products and services and outperformance relative to many industry peers.

Weaknesses

• Competitive Scale Pressure: In the Biotechnology sector, larger competitors with greater economies of scale can exert pricing pressure and outspend IDEAYA Biosciences, Inc. on marketing, R&D, and distribution — limiting the company's ability to defend market share in a price-sensitive environment.
• Market Concentration Risk: Revenue concentration in core markets or customer segments creates vulnerability to localized downturns, regulatory changes, or shifts in customer preferences. Diversification remains an ongoing strategic challenge.

Opportunities

• Total Addressable Market: IDEAYA Biosciences, Inc. operates in the Biotechnology segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for IDEAYA Biosciences, Inc.'s products and services.
• Strategic Acquisitions: With $639.39M in cash and strong free cash flow generation, IDEAYA Biosciences, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. IDEAYA Biosciences, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on IDEAYA Biosciences, Inc.'s business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

Conclusion

IDEAYA Biosciences, Inc. enters 2026 as a leading company in Healthcare, backed by $218.71 million in annual revenue and a -52.0% net profit margin. The company's -43.9% gross margins and $-52.47 million in free cash flow provide the financial foundation to fund growth initiatives while returning capital to shareholders.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in IDEAYA Biosciences, Inc.'s core markets.

For investors and analysts, IDEAYA Biosciences, Inc. represents an important company to understand within the Healthcare sector. Key metrics to track include revenue growth, margin trends, and competitive positioning updates.

Data Sources

Financial data and business information for this analysis was sourced from: Yahoo Finance – IDEAYA Biosciences, SEC EDGAR – IDEAYA Biosciences Filings, and IDEAYA Biosciences's investor relations materials.

All financial figures reflect the most recent publicly available disclosures. Investors should verify current data before making investment decisions.

Frequently Asked Questions

1. 1. What is Ideaya Biosciences known for?

IDEAYA Biosciences, Inc. generated $218.71 million in annual revenue with a -52.0% net profit margin as of the latest reporting period. The company operates in the Biotechnology sector. For the most current information, consult IDEAYA Biosciences, Inc.'s investor relations page.

2. 2. Where is Ideaya Biosciences located?

IDEAYA Biosciences, Inc. generated $218.71 million in annual revenue with a -52.0% net profit margin as of the latest reporting period. The company operates in the Biotechnology sector. For the most current information, consult IDEAYA Biosciences, Inc.'s investor relations page.

3. 3. What does the SWOT analysis of Ideaya Biosciences reveal?

IDEAYA Biosciences, Inc.'s SWOT analysis is detailed above. Key strengths: Revenue grew 55.4% year-over-year to $218.71M, indicating strong demand for IDEAYA Biosciences, Inc.'s products and services and outperformance relative to many industry peers.. Key weakness: In the Biotechnology sector, larger competitors with greater economies of scale can exert pricing pressure and outspend IDEAYA Biosciences, Inc. on marketing, R&D, and distribution — limiting the comp. Opportunities lie in Biotechnology market expansion and product innovation; threats include regulatory risk and competitive pressure.

4. 4. Who are Ideaya's main competitors?

IDEAYA Biosciences, Inc. competes in the Biotechnology segment of the Healthcare sector. The competitor comparison table in this article outlines key peers by market cap, revenue, and margins. Competitive dynamics in Biotechnology center on product differentiation, pricing strategy, and distribution scale.

5. 5. What is the significance of precision medicine in oncology?

IDEAYA Biosciences, Inc. generated $218.71 million in annual revenue with a -52.0% net profit margin as of the latest reporting period. The company operates in the Biotechnology sector. For the most current information, consult IDEAYA Biosciences, Inc.'s investor relations page.

6. 6. How does Ideaya generate revenue?

IDEAYA Biosciences, Inc. generates $218.71 million in annual revenue (TTM) with a -43.9% gross margin, growing 55.4% year-over-year. The company's revenue model is described in detail in the business model section above.

7. 7. What challenges does Ideaya face in drug development?

IDEAYA Biosciences, Inc. faces the following external threats: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. IDEAYA Biosciences, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a r Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on IDEAYA Biosciences, Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri Monitoring these risks is essential for investors tracking the company's long-term trajectory.

8. 8. What is the future outlook for Ideaya Biosciences?

IDEAYA Biosciences, Inc.'s key growth opportunities include: IDEAYA Biosciences, Inc. operates in the Biotechnology segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this envir Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for IDEAYA With $639.39M in cash and strong free cash flow generation, IDEAYA Biosciences, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reac